Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin
- PMID: 8641009
- DOI: 10.1161/01.cir.93.4.792
Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin
Abstract
Background: Thrombolysis to normal flow in patients with acute myocardial infarction preserves left ventricular function and decreases mortality. Failure of early reperfusion, reocclusion, or residual thrombus may be due to concurrent activation of the platelet-coagulation system. Thus, we hypothesized that the best concomitant antithrombotic therapy (recombinant [r]-hirudin, heparin, or aspirin) will maximally accelerate thrombolysis by r-tissue-type plasminogen activator (rTPA) and reduce residual thrombus.
Methods and results: Occlusive thrombi were formed in the carotid arteries of 29 pigs (by balloon dilatation followed by endarterectomy at the site of injury-induced vasospasm) and matured for 30 minutes before rTPA was started, with or without antithrombotic therapy. Thrombolysis was assessed with the use of angiography and measurement of residual thrombus. Pigs were allocated to one of five treatments: placebo, rTPA, rTPA plus r-hirudin, rTPA plus heparin, or rTPA plus intravenous aspirin. No placebo-treated pig reperfused. Two of six animals treated with rTPA alone reperfused compared with seven of seven animals treated with rTPA plus r-hirudin (reperfusion time, 33 +/- 10 minutes), six of seven animals treated with rTPA plus heparin (reperfusion time, 110 +/- 31 minutes), and two of six animals with rTPA plus aspirin. The activated partial thromboplastin time was prolonged in only the rTPA plus r-hirudin group (25 +/- 0.1 times baseline) and the rTPA plus heparin group (5.3 +/- 0.2 times baseline). Residual 111In-platelet and 125I-fibrin(ogen) depositions were lower in the heparin-treated group and lowest in the r-hirudin-treated group (heparin versus hirudin, respectively; incidence of residual macroscopic thrombus was six of six animals versus two of seven [P = .01]; 125I-fibrin(ogen), 170 +/- 76 versus 48 +/- 6 x 10(6) molecules/cm2 [P = .02]; 111In-platelets, 47 +/- 15 versus 13 +/- 2 x 10(6)/cm2, P = .10). No pigs developed spontaneous bleeding.
Conclusions: Thrombin inhibition with heparin or r-hirudin significantly accelerated thrombolysis of occlusive platelet-rich thrombosis, but only the best antithrombotic therapy (r-hirudin) eliminated or nearly eliminated residual thrombus.
Similar articles
-
Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.Thromb Haemost. 1997 Oct;78(4):1278-85. Thromb Haemost. 1997. PMID: 9364998
-
Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin.Circulation. 1998 Feb 24;97(7):681-5. doi: 10.1161/01.cir.97.7.681. Circulation. 1998. PMID: 9495304
-
Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis.Circulation. 1994 Apr;89(4):1802-9. doi: 10.1161/01.cir.89.4.1802. Circulation. 1994. PMID: 8149546
-
Antithrombotic therapy and progression of coronary artery disease. Antiplatelet versus antithrombins.Circulation. 1992 Dec;86(6 Suppl):III100-10. Circulation. 1992. PMID: 1424043 Review.
-
[Aspirin and heparin in the fibrinolytic treatment of acute myocardial infarction].Rev Esp Cardiol. 1992;45 Suppl 2:21-8. Rev Esp Cardiol. 1992. PMID: 1475505 Review. Spanish.
Cited by
-
PVA gel as a potential adhesion barrier: a safety study in a large animal model of intestinal surgery.Langenbecks Arch Surg. 2014 Mar;399(3):349-57. doi: 10.1007/s00423-013-1159-1. Epub 2014 Mar 4. Langenbecks Arch Surg. 2014. PMID: 24590429
-
Composition of coronary thrombus in acute myocardial infarction.J Am Coll Cardiol. 2011 Mar 22;57(12):1359-67. doi: 10.1016/j.jacc.2010.09.077. J Am Coll Cardiol. 2011. PMID: 21414532 Free PMC article.
-
Comparison of Argatroban and Hirudin for the Reperfusion of Thrombotic Arterial Occlusion by Tissue Plasminogen Activator.J Thromb Thrombolysis. 1998 Sep;6(2):103-108. doi: 10.1023/A:1008889202725. J Thromb Thrombolysis. 1998. PMID: 10751791
-
A thromboembolic model for the efficacy and safety evaluation of combined mechanical and pharmacologic revascularization strategies.J Neurointerv Surg. 2013 May;5 Suppl 1(Suppl 1):i85-9. doi: 10.1136/neurintsurg-2012-010435. Epub 2012 Sep 8. J Neurointerv Surg. 2013. PMID: 22962414 Free PMC article.
-
Degree of luminal narrowing and composition of thrombus in plaque erosion.J Thromb Thrombolysis. 2021 Jan;51(1):143-150. doi: 10.1007/s11239-020-02159-8. J Thromb Thrombolysis. 2021. PMID: 32472306 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical